Sudarshan Chemicals Posts Healthy Q3 Performance In Weak Demand Scenario: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Sudarshan Chemical Industries Ltd. reported a healthy Q3 FY21 performance in an otherwise weak demand scenario.
Sales grew by 19.6% YoY to Rs 5.06 billion (our estimate Rs 4.2 billion).
Gross margins remained flattish on a YoY basis at 42.8%. Ebitda grew by 26.5% YoY to Rs 796 million (our estimate Rs 641million), with healthy Ebitda margin of 15.7% (up 90 basis points YoY).
Profit after tax growth too beat our estimates as the company reported a growth of 38.3% YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.